Life sciences organizations are under growing pressure to process scientific evidence faster as medical congresses generate an increasing volume of competitive data across oncology, immunology, cardiology, and rare disease research. Against that backdrop, Prezent Vivo and Nested Knowledge announced a strategic partnership designed to help pharmaceutical and biotech teams accelerate congress intelligence, literature synthesis, and scientific communications using artificial intelligence.

The partnership combines Prezent Vivo’s AI-assisted scientific communication platform with Nested Knowledge’s automated evidence synthesis technology to create a unified workflow for competitive intelligence in life sciences. The companies say the collaboration will help medical affairs, commercial, HEOR, and market access teams transform raw clinical evidence into congress-ready briefings and ongoing intelligence updates in a fraction of the traditional timeline.

The announcement reflects a broader shift across the pharmaceutical industry, where AI tools are increasingly being deployed to streamline evidence review, scientific content generation, and launch planning. Large pharmaceutical companies are facing mounting operational complexity as the number of published clinical studies, conference abstracts, and treatment comparisons continues to rise.

Nested Knowledge’s AutoLit platform is designed to automate systematic literature reviews and evidence synthesis, an area traditionally associated with lengthy manual workflows and high consulting costs. According to the companies, the platform can reduce systematic review timelines by more than 70% while generating rapid evidence assessments in under 30 minutes.

Prezent Vivo, meanwhile, focuses on translating scientific evidence into business-ready communications using a hybrid AI and human expertise model. That combination is becoming increasingly common across enterprise AI deployments, particularly in regulated industries where accuracy, compliance, and contextual interpretation remain critical.

Together, the companies aim to solve a longstanding operational challenge in life sciences: transforming fragmented scientific evidence into actionable intelligence before major congresses such as ASCO Annual Meeting, European Hematology Association Congress, EULAR Congress, and American Diabetes Association Scientific Sessions.

For pharmaceutical organizations, those meetings often shape competitive strategy for entire therapeutic categories. New clinical trial endpoints, biomarker discoveries, and treatment comparisons presented during congress sessions can influence market access positioning, physician engagement strategies, and commercialization plans almost immediately.

The companies say their integrated offering will deliver pre-congress intelligence packages, living evidence updates, and on-demand competitive analysis tailored to specific therapeutic areas and internal stakeholders. Instead of commissioning separate reviews and manually assembling presentations, teams could receive continuously updated competitive intelligence in presentation-ready formats.

The timing is significant. June represents one of the busiest periods in the medical congress calendar, with oncology, hematology, thrombosis, and specialty care conferences releasing major volumes of clinical data within weeks of each other. Pharmaceutical launch teams increasingly need near real-time synthesis of competitor activity, especially in crowded therapeutic markets where differentiation depends on rapidly evolving evidence.

Industry analysts have identified evidence management and AI-driven knowledge orchestration as emerging priorities for enterprise healthcare technology investment. Gartner has projected that generative AI will influence a growing share of enterprise knowledge workflows by 2027, while McKinsey & Company has estimated that generative AI could unlock billions of dollars in productivity gains across pharmaceutical R&D, medical affairs, and commercial operations.

The partnership also illustrates how specialized AI vendors are moving beyond standalone automation tools toward integrated operating models. Rather than positioning AI purely as a content-generation layer, companies are increasingly combining data ingestion, evidence synthesis, workflow automation, and expert review into unified enterprise systems.

That approach mirrors broader developments across enterprise software ecosystems led by companies such as Microsoft, Google, Salesforce, and Adobe, all of which are embedding generative AI into workflow-centric productivity platforms rather than standalone applications.

For life sciences organizations, the competitive advantage may ultimately depend less on access to data and more on how quickly teams can operationalize scientific insights. Congress intelligence has historically been fragmented across agencies, consultants, internal analysts, and medical communications vendors. Integrated AI-powered evidence ecosystems could significantly compress that workflow.

The partnership between Prezent Vivo and Nested Knowledge signals how AI adoption in life sciences is moving beyond experimentation into operational infrastructure. As medical congresses generate increasingly complex streams of competitive information, pharmaceutical organizations are likely to prioritize platforms capable of converting evidence into decision-ready intelligence with greater speed and consistency.

Market Landscape

The life sciences AI market is rapidly evolving as pharmaceutical companies seek faster ways to synthesize clinical evidence, monitor competitors, and support commercialization decisions. AI-powered evidence synthesis platforms are increasingly competing alongside traditional medical communications agencies and enterprise analytics vendors.

Companies across the healthcare technology ecosystem are investing heavily in AI-driven research automation, scientific search, and knowledge management. Enterprise demand is rising for platforms that combine natural language processing, literature review automation, and scientific communications within a single workflow.

According to IDC, global enterprise AI spending continues to accelerate across regulated industries, while healthcare organizations are prioritizing automation tools capable of reducing manual administrative and research workloads. In parallel, life sciences teams are under pressure to shorten launch timelines and respond faster to competitor developments presented at global congresses.

The Prezent Vivo and Nested Knowledge partnership positions both companies within a growing category of AI-enabled scientific intelligence platforms serving pharmaceutical commercialization and medical affairs operations.

Top Insights

• Prezent Vivo and Nested Knowledge combined AI-powered evidence synthesis and scientific communications to accelerate competitive intelligence workflows for pharmaceutical and biotech organizations.
• The partnership targets medical congress preparation, helping life sciences teams analyze competitor data, clinical evidence, and KOL positioning before major scientific meetings begin.
• Nested Knowledge’s AutoLit platform reportedly reduces systematic review timelines by more than 70%, addressing operational bottlenecks in evidence synthesis and literature analysis.
• The collaboration reflects broader enterprise adoption of AI workflow platforms that combine automation, human expertise, and real-time scientific intelligence for regulated industries.
• Pharmaceutical commercial, medical affairs, HEOR, and market access teams could benefit from faster access to presentation-ready evidence and ongoing living-literature updates.

Get in touch with our MarTech Experts